miR-19a and miR-421 target PCA3 long non-coding RNA and restore PRUNE2 tumor suppressor activity in prostate cancer

E Bozgeyik, S Kocahan, E Temiz, H Bagis - Molecular Biology Reports, 2021 - Springer
Background Prostate cancer antigen 3 (PCA3) is the most promising diagnostic biomarker
for the differential diagnosis of prostate cancer identified to date. As a dominant-negative …

External validation of two MRI-based risk calculators in prostate cancer diagnosis

AL Petersmann, S Remmers, T Klein, P Manava… - World Journal of …, 2021 - Springer
Background The diagnosis of (significant) prostate cancer ((s) PC) is impeded by
overdiagnosis and unnecessary biopsy. Risk calculators (RC) have been developed to …

[HTML][HTML] Voided urine test to diagnose prostate cancer: Preliminary report

RB Nerli, SC Ghagane, SR Bidi, ML Thakur… - …, 2021 - ncbi.nlm.nih.gov
Objectives: Prostate cancer (PCa) is a common malignancy affecting elderly male. At
present, PCa is estimated using serum prostate-specific antigen (PSA). Prostate biopsy …

Influencia del protocolo diagnóstico y la edad en la tasa de incidencia de cáncer de próstata en Castilla y León según el registro nacional de 2010

MI Gutiérrez-Pérez, M González-Sagrado… - Actas Urológicas …, 2021 - Elsevier
Objetivo Estudio observacional descriptivo transversal de incidencia y asociación, para
conocer si la mayor incidencia de cáncer de próstata en Castilla y León (respecto a la tasa …

[PDF][PDF] CAP study

RM Martin, JL Donovan, FC Hamdy, DE Neal… - captrial.blogs.bristol.ac.uk
Technical and operational elements are subject to regular re-specification, therefore
separate Standard Operating Procedures (SOPs) are summarized and referenced here only …